Topical hexapeptide marketed for temporary softening of expression lines.
Acetyl-EEMQRR-NH2. Derived from the N-terminus of SNAP-25; proposed to interfere with SNARE complex formation and thereby reduce muscle-contraction wrinkles when delivered topically.
Evidence summary in progress. See the citations section below for the underlying research papers.
No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.
No documented drug interactions on file.
Not FDA approved as a drug. Used as a cosmetic ingredient.
Not available via 503A/503B compounding pharmacies.
Regulatory data last verified 4/19/2026
Showing 20 of 30 papers. View all on PubMed →